- Home
- MLP vs CTNM Comparison
MLP vs CTNM Comparison
Compare MLP & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLP
- CTNM
- Stock Information
- Founded
- MLP 1909
- CTNM 2009
- Country
- MLP United States
- CTNM United States
- Employees
- MLP N/A
- CTNM N/A
- Industry
- MLP Real Estate
- CTNM
- Sector
- MLP Finance
- CTNM
- Exchange
- MLP Nasdaq
- CTNM Nasdaq
- Market Cap
- MLP 341.6M
- CTNM 328.1M
- IPO Year
- MLP 1972
- CTNM 2024
- Fundamental
- Price
- MLP $15.50
- CTNM $10.44
- Analyst Decision
- MLP
- CTNM Strong Buy
- Analyst Count
- MLP 0
- CTNM 5
- Target Price
- MLP N/A
- CTNM $22.20
- AVG Volume (30 Days)
- MLP 17.7K
- CTNM 97.8K
- Earning Date
- MLP 11-14-2025
- CTNM 10-30-2025
- Dividend Yield
- MLP N/A
- CTNM N/A
- EPS Growth
- MLP N/A
- CTNM N/A
- EPS
- MLP N/A
- CTNM N/A
- Revenue
- MLP $16,843,000.00
- CTNM N/A
- Revenue This Year
- MLP N/A
- CTNM N/A
- Revenue Next Year
- MLP N/A
- CTNM N/A
- P/E Ratio
- MLP N/A
- CTNM N/A
- Revenue Growth
- MLP 74.59
- CTNM N/A
- 52 Week Low
- MLP $14.05
- CTNM $3.35
- 52 Week High
- MLP $25.78
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- MLP 42.84
- CTNM 43.29
- Support Level
- MLP $14.71
- CTNM $10.16
- Resistance Level
- MLP $16.44
- CTNM $11.30
- Average True Range (ATR)
- MLP 0.73
- CTNM 0.69
- MACD
- MLP -0.02
- CTNM -0.15
- Stochastic Oscillator
- MLP 34.29
- CTNM 12.02
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.